{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:26:52Z","timestamp":1722385612439},"reference-count":54,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.mcna.2024.02.005","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T07:30:24Z","timestamp":1717572624000},"page":"895-910","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Update on Therapies in Older Adults"],"prefix":"10.1016","volume":"108","author":[{"given":"Sophie","family":"Clark","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Runkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.mcna.2024.02.005_bib1","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1001\/jama.2014.13806","article-title":"The diagnosis and management of mild cognitive impairment: a clinical review","volume":"312","author":"Langa","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2024.02.005_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.719849","article-title":"Diagnosis and treatment for mild cognitive impairment: A systematic review of clinical practice guidelines and consensus statements","volume":"12","author":"Chen","year":"2021","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.mcna.2024.02.005_bib3","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1519\/JPT.0000000000000218","article-title":"Tai Chi combined with resistance training for adults aged 50 years and older: A systematic review","volume":"43","author":"Qi","year":"2020","journal-title":"J\u00a0Geriatr Phys Ther"},{"issue":"1","key":"10.1016\/j.mcna.2024.02.005_bib4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/jgs.12611","article-title":"Effect of Tai Chi on cognitive performance in older adults: Systematic Review and meta-analysis","volume":"62","author":"Wayne","year":"2014","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"4","key":"10.1016\/j.mcna.2024.02.005_bib5","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/jgs.14594","article-title":"Effects of Tai Chi on cognition and fall risk in older adults with mild cognitive impairment: A randomized controlled trial","volume":"65","author":"Sungkarat","year":"2016","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"4","key":"10.1016\/j.mcna.2024.02.005_bib6","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.7004","article-title":"Effects of Tai Chi Chuan on cognitive function in adults 60 years or older with type 2 diabetes and mild cognitive impairment in China","volume":"6","author":"Chen","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.mcna.2024.02.005_bib7","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.7326\/M23-1603","article-title":"Clinical effectiveness of cognitively enhanced tai ji quan training on global cognition and dual-task performance during walking in older adults with mild cognitive impairment or self-reported memory concerns","volume":"176","author":"Li","year":"2023","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.mcna.2024.02.005_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.8112","article-title":"Association of hearing loss with dementia","volume":"2","author":"Liu","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1016\/j.mcna.2024.02.005_bib9","first-page":"1383","article-title":"Death, depression, disability, and dementia associated with self-reported hearing problems: A 25-year study","volume":"73","author":"Amieva","year":"2018","journal-title":"J\u00a0Gerontol: Series A"},{"issue":"10404","key":"10.1016\/j.mcna.2024.02.005_bib10","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0140-6736(23)01406-X","article-title":"Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (achieve): A Multicentre, randomised controlled trial","volume":"402","author":"Lin","year":"2023","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.mcna.2024.02.005_bib11","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.0b013e31828726f5","article-title":"Alzheimer disease in the United States (2010-2050) estimated using the 2010 census","volume":"80","author":"Hebert","year":"2013","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.mcna.2024.02.005_bib12","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1111\/j.1532-5415.2012.04077.x","article-title":"Contribution of individual diseases to death in older adults with multiple diseases","volume":"60","author":"Tinetti","year":"2012","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"6","key":"10.1016\/j.mcna.2024.02.005_bib13","article-title":"Donepezil for dementia due to alzheimer\u2019s disease","volume":"6","author":"Birks","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"26","key":"10.1016\/j.mcna.2024.02.005_bib14","article-title":"The clinical meaningfulness of ADAS-COG changes in Alzheimer\u2019s disease patients treated with donepezil in an open-label trial","volume":"7","author":"Rockwood","year":"2007","journal-title":"BMC Neurol"},{"issue":"3","key":"10.1016\/j.mcna.2024.02.005_bib15","article-title":"Memantine for dementia","volume":"3","author":"McShane","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.mcna.2024.02.005_bib16","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to alzheimer\u2019s disease: recommendations from the national institute on aging-alzheimer\u2019s association workgroups on diagnostic guidelines for alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"5054","key":"10.1016\/j.mcna.2024.02.005_bib17","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer\u2019s disease: the amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"issue":"7618","key":"10.1016\/j.mcna.2024.02.005_bib18","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces a\u03b2 plaques in alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.mcna.2024.02.005_bib20","first-page":"197","article-title":"Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer\u2019s Disease","volume":"9","author":"Haeberlein","year":"2022","journal-title":"J\u00a0Prev Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.mcna.2024.02.005_bib21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer\u2019s Disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.mcna.2024.02.005_bib22","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1001\/archneur.65.8.1091","article-title":"Staging Dementia Using Clinical Dementia Rating Scale Sum of Boxes Scores: A Texas Alzheimer\u2019s Research Consortium Study","volume":"65","author":"O\u2019Bryant","year":"2008","journal-title":"Arch Neurol"},{"issue":"9","key":"10.1016\/j.mcna.2024.02.005_bib23","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1056\/NEJMp2110468","article-title":"Revisiting FDA Approval of Aducanumab","volume":"385","author":"Alexander","year":"2021","journal-title":"N\u00a0Engl J Med"},{"year":"2023","series-title":"ADUHELM\u00ae (aducanumab-avwa) [package insert]","key":"10.1016\/j.mcna.2024.02.005_bib24"},{"year":"2023","series-title":"[package insert]","key":"10.1016\/j.mcna.2024.02.005_bib25"},{"issue":"1","key":"10.1016\/j.mcna.2024.02.005_bib26","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2022.0048","article-title":"Medicare to Cover Controversial Alzheimer Disease Drug Only in Clinical Trials","volume":"3","author":"Stephenson","year":"2022","journal-title":"JAMA Health Forum"},{"year":"2023","series-title":"CMS National patient Registry for New Alzheimer\u2019s Drugs: things to know for clinicians","key":"10.1016\/j.mcna.2024.02.005_bib29"},{"issue":"8","key":"10.1016\/j.mcna.2024.02.005_bib32","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/jamainternmed.2023.1749","article-title":"Estimated Annual Spending on Lecanemab and Its Ancillary costs in the US Medicare Program","volume":"183","author":"Arbanas","year":"2023","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.mcna.2024.02.005_bib33","first-page":"1","article-title":"Agitation in cognitive disorders: Progress in the International Psychogeriatric Association Consensus Clinical and Research Definition","author":"Sano","year":"2023","journal-title":"Int Psychogeriatr"},{"issue":"3","key":"10.1016\/j.mcna.2024.02.005_bib34","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3390\/pharmacy10030061","article-title":"A\u00a0narrative review of studies comparing efficacy and safety of citalopram with atypical antipsychotics for agitation in behavioral and psychological symptoms of dementia (BPSD)","volume":"10","author":"Qasim","year":"2022","journal-title":"Pharmacy"},{"issue":"3","key":"10.1016\/j.mcna.2024.02.005_bib35","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.0828","article-title":"Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia","volume":"2","author":"Yunusa","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.mcna.2024.02.005_bib36","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1124\/jpet.114.213793","article-title":"Brexpiprazole I: In\u00a0vitro and in\u00a0vivo characterization of a novel serotonin-dopamine activity modulator","volume":"350","author":"Maeda","year":"2014","journal-title":"J\u00a0Pharmacol Exp Therapeut"},{"key":"10.1016\/j.mcna.2024.02.005_bib37","unstructured":"For Rexulti. highlights of prescribing information rexulti safely. Available at: https:\/\/www.otsuka-us.com\/sites\/g\/files\/qhldwo8366\/files\/media\/static\/Rexulti-PI.pdf. Accessed November 19, 2023."},{"key":"10.1016\/j.mcna.2024.02.005_bib38","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2023.3810","article-title":"Brexpiprazole for the treatment of agitation in alzheimer dementia","author":"Lee","year":"2023","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.mcna.2024.02.005_bib39","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jagp.2019.09.009","article-title":"Efficacy and safety of Brexpiprazole for the treatment of agitation in alzheimer\u2019s dementia: Two 12-week, randomized, double-blind, placebo-controlled trials","volume":"28","author":"Grossberg","year":"2020","journal-title":"Am J Geriatr Psychiatr"},{"key":"10.1016\/j.mcna.2024.02.005_bib40","article-title":"Cohen-mansfield agitation inventory","author":"Cohen-Mansfield","year":"1986","journal-title":"PsycTESTS Dataset"},{"key":"10.1016\/j.mcna.2024.02.005_bib41","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2023.3967","article-title":"Brexpiprazole for the treatment of agitation and aggression in alzheimer disease","author":"Ballard","year":"2023","journal-title":"JAMA Neurology"},{"key":"10.1016\/j.mcna.2024.02.005_bib42","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","article-title":"The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society","volume":"61","author":"Abrams","year":"2003","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.mcna.2024.02.005_bib43","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.urology.2010.08.039","article-title":"National community prevalence of overactive bladder in the United States stratified by sex and age","volume":"77","author":"Coyne","year":"2011","journal-title":"Urology"},{"issue":"10","key":"10.1016\/j.mcna.2024.02.005_bib44","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/ijcp.12164","article-title":"Comorbidities and personal burden of urgency urinary incontinence: a systematic review","volume":"67","author":"Coyne","year":"2013","journal-title":"Int J Clin Pract"},{"issue":"10","key":"10.1016\/j.mcna.2024.02.005_bib45","first-page":"CD013571","article-title":"Bladder training for treating overactive bladder in adults","volume":"10","author":"Funada","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.mcna.2024.02.005_bib46","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.maturitas.2020.09.005","article-title":"Management of urinary incontinence in postmenopausal women: an EMAS clinical guide","volume":"143","author":"Russo","year":"2020","journal-title":"Maturitas"},{"issue":"7","key":"10.1016\/j.mcna.2024.02.005_bib47","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1111\/jgs.18372","article-title":"American Geriatrics Society 2023 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults","volume":"71","year":"2023","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"2","key":"10.1016\/j.mcna.2024.02.005_bib48","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1124\/jpet.106.115840","article-title":"Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function","volume":"321","author":"Takasu","year":"2007","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.mcna.2024.02.005_bib49","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s40261-013-0084-y","article-title":"Role of cytochrome p450 isoenzymes 3A and 2D6 in the in\u00a0vivo metabolism of mirabegron, a \u03b23-adrenoceptor agonist","volume":"33","author":"Lee","year":"2013","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.mcna.2024.02.005_bib50","unstructured":"Astellas Pharma US Inc, MYRBETRIQ\u00ae (mirabegron extended-release tablets). Full prescribing information, 2018, Astellas Pharma US Inc. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/202611s011lbl.pdf."},{"issue":"1","key":"10.1016\/j.mcna.2024.02.005_bib51","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/sj.tpj.6500285","article-title":"Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity","volume":"5","author":"Ingelman-Sundberg","year":"2005","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.mcna.2024.02.005_bib52","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1021\/acs.jmedchem.5b01372","article-title":"Discovery of vibegron: a potent and selective b3 adrenergic receptor agonist for the treatment of overactive bladder","volume":"59","author":"Edmondson","year":"2016","journal-title":"J\u00a0Med Chem"},{"issue":"2","key":"10.1016\/j.mcna.2024.02.005_bib53","first-page":"316","article-title":"International Phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR","volume":"204","author":"Staskin","year":"2020","journal-title":"J\u00a0Urol"},{"issue":"5","key":"10.1016\/j.mcna.2024.02.005_bib54","doi-asserted-by":"crossref","first-page":"e23171","DOI":"10.1097\/MD.0000000000023171","article-title":"Systematic review and meta-analysis of the efficacy and safety of vibegron vs antimuscarinic monotherapy for overactive bladder","volume":"100","author":"Su","year":"2021","journal-title":"Medicine (Baltim)"},{"issue":"8","key":"10.1016\/j.mcna.2024.02.005_bib55","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/ijcp.12433","article-title":"Safety and tolerability of the \u03b23-adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial","volume":"68","author":"Nitti","year":"2014","journal-title":"Int J Clin Pract"},{"issue":"3","key":"10.1016\/j.mcna.2024.02.005_bib56","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/luts.12475","article-title":"Efficacy and safety of vibegron compared with mirabegron for overactive bladder: A systematic review and network meta-analysis","volume":"15","author":"He","year":"2023","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.mcna.2024.02.005_bib57","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.urology.2023.02.003","article-title":"Comparison of mirabegron and vibegron in women with treatment-naive overactive bladder: a randomized controlled study","volume":"175","author":"Kinjo","year":"2023","journal-title":"Urology"},{"issue":"11","key":"10.1016\/j.mcna.2024.02.005_bib58","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1007\/s12325-021-01902-8","article-title":"Efficacy of vibegron and mirabegron for overactive bladder: a systematic literature review and indirect treatment comparison","volume":"38","author":"Kennelly","year":"2021","journal-title":"Adv Ther"},{"issue":"12","key":"10.1016\/j.mcna.2024.02.005_bib59","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11934-017-0739-y","article-title":"New devices and technologies for the management of overactive bladder","volume":"18","author":"Guzman-Negron","year":"2017","journal-title":"Curr Urol Rep"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712524000178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712524000178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T06:10:59Z","timestamp":1722319859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712524000178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0025712524000178"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2024.02.005","relation":{},"ISSN":["0025-7125"],"issn-type":[{"type":"print","value":"0025-7125"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on Therapies in Older Adults","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2024.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}